ATE508191T1 - Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase - Google Patents
Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenaseInfo
- Publication number
- ATE508191T1 ATE508191T1 AT07827307T AT07827307T ATE508191T1 AT E508191 T1 ATE508191 T1 AT E508191T1 AT 07827307 T AT07827307 T AT 07827307T AT 07827307 T AT07827307 T AT 07827307T AT E508191 T1 ATE508191 T1 AT E508191T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- expression
- platelet
- type
- lipoxygenase
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 102000011730 Arachidonate 12-Lipoxygenase Human genes 0.000 title abstract 2
- 108010076676 Arachidonate 12-lipoxygenase Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 108090000128 Lipoxygenases Proteins 0.000 abstract 3
- 102000003820 Lipoxygenases Human genes 0.000 abstract 2
- 210000001789 adipocyte Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000030279 gene silencing Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 210000000229 preadipocyte Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85573606P | 2006-11-01 | 2006-11-01 | |
| PCT/IL2007/001333 WO2008053487A2 (en) | 2006-11-01 | 2007-11-01 | Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE508191T1 true ATE508191T1 (de) | 2011-05-15 |
Family
ID=39251348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07827307T ATE508191T1 (de) | 2006-11-01 | 2007-11-01 | Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9279127B2 (de) |
| EP (1) | EP2078079B1 (de) |
| AT (1) | ATE508191T1 (de) |
| CA (1) | CA2667971C (de) |
| DE (1) | DE602007014389D1 (de) |
| IL (1) | IL198421A (de) |
| WO (1) | WO2008053487A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2525658B1 (de) | 2010-01-22 | 2017-03-01 | Bayer Intellectual Property GmbH | Akarizide und/oder insektizide wirkstoffkombinationen |
| WO2013020985A1 (en) | 2011-08-10 | 2013-02-14 | Bayer Intellectual Property Gmbh | Active compound combinations comprising specific tetramic acid derivatives |
| US20140178456A1 (en) * | 2012-08-30 | 2014-06-26 | Udaya Sankar Devanaboyina | Methods and compositions for treating type 2 diabetes and related conditions |
| EP3449001B1 (de) | 2016-04-29 | 2021-12-08 | Aptamir Therapeutics, Inc. | Hemmung von mir-22-mirna durch apt-110 |
| JP2020521464A (ja) * | 2017-05-26 | 2020-07-27 | マーシャル ユニバーシティー リサーチ コーポレーションＭａｒｓｈａｌｌ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｃｏｒｐｏｒａｔｉｏｎ | Ｎａ／Ｋ ＡＴＰアーゼ／Ｓｒｃ受容体複合体アンタゴニストの送達の発現ベクターおよび関連する方法 |
| EP4089412A4 (de) * | 2020-03-24 | 2023-01-25 | Hirata Corporation | Beobachtungshalter, beobachtungsvorrichtung, beobachtungschip und herstellungsverfahren dafür |
| KR20230113346A (ko) * | 2020-11-25 | 2023-07-28 | 플래그쉽 파이어니어링, 인크. | 지방생성 세포 조성물 및 방법 |
| WO2024159175A2 (en) * | 2023-01-27 | 2024-08-02 | Oisin Biotechnologies, Inc. | Compositions, systems, and methods for reducing adipose tissue |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| JP2507895B2 (ja) | 1989-12-19 | 1996-06-19 | 工業技術院長 | リボザイムの新規合成系 |
| US5631115A (en) | 1992-07-02 | 1997-05-20 | Sankyo Company, Limited | Looped, hairpin ribozyme |
| US6191169B1 (en) * | 1992-08-28 | 2001-02-20 | City Of Hope | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states |
| US20060084061A1 (en) | 2002-06-11 | 2006-04-20 | Marcusson Eric G | Methods for blocking adipocyte differentiation and triglyceride accumulation with interleukin 12 p35 inhibitors |
| US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
| US5545729A (en) | 1994-12-22 | 1996-08-13 | Hybridon, Inc. | Stabilized ribozyme analogs |
| US5861268A (en) | 1996-05-23 | 1999-01-19 | Biomide Investment Limited Partnership | Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase |
| US20050261485A1 (en) | 1996-05-23 | 2005-11-24 | Toagosei Co., Ltd., A Japan Corporation | Method of producing antisense oligonucleotide |
| US5869037A (en) * | 1996-06-26 | 1999-02-09 | Cornell Research Foundation, Inc. | Adenoviral-mediated gene transfer to adipocytes |
| EP0856579A1 (de) | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden |
| WO1999001139A1 (en) | 1997-07-03 | 1999-01-14 | Thomas Jefferson University | An improved method for design and selection of efficacious antisense oligonucleotides |
| WO2006094406A1 (en) | 2005-03-11 | 2006-09-14 | Sarissa Inc. | Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof |
| EP1023064A1 (de) * | 1997-10-15 | 2000-08-02 | City Of Hope | 12(s)-hete receptor blocker |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AU3905599A (en) * | 1998-05-20 | 1999-12-06 | City Of Hope | Method of treating or preventing abnormal cardiac cell growth by inhibiting the 12-lipoxygenase pathway |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| CA2362586A1 (en) * | 1999-02-12 | 2000-08-17 | Genset S.A. | Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism |
| US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
| FR2790757B1 (fr) | 1999-03-09 | 2003-08-01 | Bioalliance Pharma | Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant. |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| AU4671300A (en) * | 1999-04-30 | 2000-11-17 | City Of Hope | The use of adeno-associated virus (aav) deliver cytoprotective genes |
| RU2164944C1 (ru) | 1999-12-09 | 2001-04-10 | Институт молекулярной биологии им. В.А. Энгельгардта РАН | Способ изменения генетических свойств организма |
| EP1309726B2 (de) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Mediatoren von rns-interferenz, die rns-sequenzspezifisch sind |
| WO2001076588A1 (en) | 2000-04-06 | 2001-10-18 | Coastside Research | Method to inhibit lipoxygenase and cancer cell proliferation |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20060217331A1 (en) | 2001-05-18 | 2006-09-28 | Sirna Therapeutics, Inc. | Chemically modified double stranded nucleic acid molecules that mediate RNA interference |
| AU2003281867A1 (en) * | 2002-03-28 | 2004-02-23 | University Of Florida | Antisense nucleic acids |
| US20060122131A1 (en) | 2002-06-11 | 2006-06-08 | Marcusson Eric G | Methods for blocking adipocyte differentiation and triglyceride accumulation with transcription factor dp-1 inhibitors |
| AU2003243486A1 (en) | 2002-06-11 | 2003-12-22 | Isis Pharmaceuticals, Inc. | Methods for blocking adipocyte differentiation and triglyceride accumulation with g-alpha-i3 inhibitors |
| WO2004029070A2 (en) | 2002-09-24 | 2004-04-08 | Isis Pharmaceutical, Inc. | Methods for blocking adipocyte differentiation and triglyceride accumulation with dual-specificity tyrosine- (y) - phosphorylation regulated kinase 4 (dyrk4) inhibitors |
| WO2004041197A2 (en) | 2002-11-01 | 2004-05-21 | Case Western Reserve University | Methods of inhibiting glial scar formation |
| US7585623B2 (en) * | 2002-12-26 | 2009-09-08 | Ono Pharmaceutical Co., Ltd. | Adiponectin promoter and use thereof |
| EP1601767B1 (de) | 2003-03-05 | 2012-04-25 | Senesco Technologies, Inc. | Verwendung von sirna zur abschaffung der expression von eif-5a1 in der behandlung von glaukoma |
| JP4742032B2 (ja) * | 2004-03-31 | 2011-08-10 | 株式会社東京大学Ｔｌｏ | アディポネクチン発現誘導剤およびその利用 |
| US20060078902A1 (en) | 2004-04-15 | 2006-04-13 | Michaeline Bunting | Method and compositions for RNA interference |
| WO2006039285A2 (en) | 2004-09-30 | 2006-04-13 | The University Of Georgia Research Foundation, Inc. | Compositions and methods for inducing adipose tissue cell death |
| US7608277B2 (en) | 2004-12-01 | 2009-10-27 | Gene Therapy Systems, Inc. | Tuberculosis nucleic acids, polypeptides and immunogenic compositions |
| JP2008521909A (ja) | 2004-12-02 | 2008-06-26 | ビー−ブリッジ インターナショナル，インコーポレーテッド | 短鎖干渉ｒｎａ、アンチセンスポリヌクレオチド、および他のハイブリッド形成化ポリヌクレオチドの設計方法 |
| US20100150885A1 (en) * | 2005-06-01 | 2010-06-17 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
-
2007
- 2007-11-01 AT AT07827307T patent/ATE508191T1/de not_active IP Right Cessation
- 2007-11-01 WO PCT/IL2007/001333 patent/WO2008053487A2/en not_active Ceased
- 2007-11-01 DE DE602007014389T patent/DE602007014389D1/de active Active
- 2007-11-01 US US12/513,006 patent/US9279127B2/en not_active Expired - Fee Related
- 2007-11-01 EP EP07827307A patent/EP2078079B1/de not_active Not-in-force
- 2007-11-01 CA CA2667971A patent/CA2667971C/en not_active Expired - Fee Related
-
2009
- 2009-04-27 IL IL198421A patent/IL198421A/en active IP Right Grant
-
2015
- 2015-02-16 US US14/623,074 patent/US9663790B2/en not_active Expired - Fee Related
-
2017
- 2017-05-30 US US15/607,815 patent/US20170327827A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2667971A1 (en) | 2008-05-08 |
| US20170327827A1 (en) | 2017-11-16 |
| WO2008053487A3 (en) | 2008-06-19 |
| US9279127B2 (en) | 2016-03-08 |
| IL198421A0 (en) | 2011-08-01 |
| EP2078079A2 (de) | 2009-07-15 |
| US20150191734A1 (en) | 2015-07-09 |
| CA2667971C (en) | 2017-04-18 |
| US20110038923A1 (en) | 2011-02-17 |
| DE602007014389D1 (de) | 2011-06-16 |
| EP2078079B1 (de) | 2011-05-04 |
| WO2008053487A2 (en) | 2008-05-08 |
| US9663790B2 (en) | 2017-05-30 |
| IL198421A (en) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE508191T1 (de) | Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase | |
| MX2022009707A (es) | Vacunas de dominio de arnm contra el sars-cov-2. | |
| ZA201902226B (en) | Aav treatment of huntington's disease | |
| EA201290572A1 (ru) | Растения, устойчивые к гербицидам - ингибиторам hppd | |
| EA201290560A1 (ru) | Растения, устойчивые к гербицидам - ингибиторам hppd | |
| NZ589230A (en) | Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means | |
| DE60143901D1 (de) | Antisense-modulation der clusterinexpression | |
| ATE453716T1 (de) | Verfahren zur modulation der genexpression durch änderung des cpg gehalts | |
| EA200800868A1 (ru) | Модуляция экспрессии глюкокортикоидного рецептора | |
| ATE513843T1 (de) | Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna | |
| AU2009236219A8 (en) | Silencing of CSN5 gene expression using interfering RNA | |
| EA201100813A1 (ru) | Фармацевтическая композиция | |
| EA201001393A1 (ru) | Липазы с высокой специфичностью к жирным кислотам с короткой цепью и их использование | |
| WO2010017436A3 (en) | Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides | |
| WO2004033620A3 (en) | Methods and compositions for therapeutic use of rna interference | |
| TW200502385A (en) | Modulation of forkhead box o1a expression | |
| WO2006081546A3 (en) | Inhibitor nucleic acids | |
| PH12013502049A1 (en) | Modulation of signal transducer and activator of transcription 3 (stat3) expression | |
| TNSN08252A1 (en) | Sirna anti myosine va et depigmentation de la peau | |
| WO2004071407A3 (en) | Antisense modulation of ptp1b expression | |
| IN2014CN03921A (de) | ||
| NZ741841A (en) | Antisense oligonucleotides for use in treating alzheimer’s disease | |
| EA201171144A1 (ru) | ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) | |
| EA201100847A1 (ru) | Опосредованное рнк-интерференцией ингибирование экспрессии генов эпителиального натриевого канала (enac) c использованием малой интерферирующей нуклеиновой кислоты (минк) | |
| WO2009105572A3 (en) | Antisense modulation of amyloid beta protein expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |